Aspen Neuroscience prices $141M IPO to fund Parkinson's cell therapy
- Aspen Neuroscience sold about 9.4 million shares at $15, the low end of its range, raising roughly $140.6 million; trading began under ticker ASPE.
- Proceeds will advance sasineprocel, a one-time therapy using a patient's own skin cells turned into dopamine-producing neurons; a Phase 3 start is targeted by end of next year.
- Bambusa Therapeutics also priced an offering, bringing 2026 US biotech IPOs to 29, the most since 2021.
💡 Points Based on public reports
Pricing at the bottom of the range says public investors will fund autologous cell therapy, but only at a discount. Roughly $141M is thin for a Phase 3 in Parkinson's with bespoke, patient-specific manufacturing, so Aspen will likely need a follow-on or partner before data. Its edge over allogeneic rivals is avoiding immunosuppression; the cost is scalability.
Aspen raises a $141M IPO in pursuit of a cell therapy for Parkinson's ↗